, California, United States • 11 - 50 Employees
Biotechnology
Oncotelic /Mateon is a convergent of PointR AI clustercomputing, Oncotelic antisense platform, and Mateon vascular disrupting agent. Lead asset OT-101 is an antisense against TGF-beta for cancer, covid-19, and other viruses